Skip to main content

Advertisement

Table 7 Prognostic markers involved in other aspects of ESCC as reported in original studies

From: Immunohistochemical prognostic markers of esophageal squamous cell carcinoma: a systematic review

Marker References Sample size Clinical stage OS DFS Analytic methods
HR 95% CI P value HR 95% CI P value
PKM2 Zhan et al. [17] 210 I–IV 1.748 1.277–2.395 <0.001 Cox proportional hazards model
Li et al. [24] 141 I–IV 1.214 0.728–2.026 0.458 Cox proportional hazards model
Zhang et al. [95] 86 I–IV 2.358 1.156–4.812 0.018 Cox proportional hazards model
Fukuda et al. [96] 205 I–IV 1.850 1.200–2.780 0.0189 Cox proportional hazards model
CXCR4 Gockel et al. [25] 53 I–III 1.472 0.836–2.593 0.181 Cox proportional hazards model
Zhang et al. [98] 136 I–IV 1.612 1.072–2.425 0.022 1.708 1.126–2.591 0.012 Cox proportional hazards model
Lu et al. [99] 127 I–III 1.720 0.749–3.928 0.202 1.497 0.659–3.399 0.335 Cox proportional hazards model
Qi et al. [100] 60 0.001 Log-rank test
Sasaki et al. [101] 214 I–IV 0.4 0.3 Log-rank test
MLH1 Tzao et al. [18] 60 I–IV 0.18 Log-rank test
Kishi et al. [104] 156 I–IV 2.020 1.146–4.231 0.018 Cox proportional hazards model
Uehara et al. [105] 122 I–IV 0.0043 Log-rank test
  1. ESCC esophageal squamous cell carcinoma, PKM2 pyruvate kinase M2, CXCR4 C-X-C chemokine receptor type 4, MLH1 mut-L-homologon-1, OS overall survival, DFS disease-free survival, HR hazard ratio, CI confidence interval, no data